← Research index · Disorder page · Source YAML

Cross-provider research synthesis

HER2 Positive Breast Cancer

MONDO:0006244 Curated 2026-07-04T00:00:00Z 9 harmonized findings

falcon · 19 citations asta · 18 citations

Concordant asserts the finding Partial supports a weaker/qualified form Contradictory conflicts with it Silent does not address it

Harmonized findings

HER2-positive breast cancer is driven by amplification/overexpression of the ERBB2 (HER2) receptor tyrosine kinase, which acts as an oncogenic driver promoting proliferation, survival, and malignant transformation.

UNANIMOUS INTEGRATED

pathophysiologygenetic_factor

Provider	Stance	Score	Evidence
falcon	CONCORDANT	95%	HER2-positive breast cancer is driven by amplification/overexpression of ERBB2 (HER2), a receptor tyrosine kinase of the ErbB/EGFR family. Falcon states the ERBB2-amplification/overexpression driver mechanism and the ErbB/EGFR receptor-tyrosine-kinase identity directly. DOI:10.3390/genes15070903
asta	CONCORDANT	90%	When amplified or overexpressed, the HER2 gene drives oncogenic signaling that promotes proliferation, survival, and malignant transformation in breast cancer Asta's retrieved literature agrees that HER2/ERBB2 amplification/overexpression is the oncogenic driver of proliferation, survival, and transformation. PMID:41595172

Overexpressed HER2 signals in a ligand-independent manner (notably via HER2/HER3 dimers) through the PI3K/AKT/mTOR and RAS/RAF/MEK/ERK (MAPK) cascades to drive proliferation and survival.

UNANIMOUS INTEGRATED

pathophysiologygene_function

Provider	Stance	Score	Evidence
falcon	CONCORDANT	95%	HER2/HER3 heterodimer is highly potent in activating downstream signaling pathways, such as PI3K/AKT and MAPK. Falcon names the HER2/HER3 dimer and the two canonical effector cascades (PI3K/AKT and MAPK) explicitly. DOI:10.3390/genes15070903
asta	CONCORDANT	90%	HER2 overexpression serves as an oncogenic driver in the progression of BC, promoting constitutive activation of downstream signaling cascades that induce cell proliferation through the Ras-mitogen-activated protein kinase (MAPK) pathway Asta's retrieved literature independently reports constitutive activation of the RAS-MAPK (and PI3K/AKT/mTOR) cascade downstream of HER2 overexpression. PMID:36627608

HER2-positive disease comprises roughly 15-25% of breast cancers and is a clinically aggressive phenotype historically associated with worse survival.

UNANIMOUS INTEGRATED

epidemiologyprognosis

Provider	Stance	Score	Evidence
falcon	CONCORDANT	90%	HER2-positive constitutes ~15–25% of breast cancers Falcon gives the 15-25% frequency band for HER2-positive breast cancer. DOI:10.3390/ijms252413376, DOI:10.3390/cancers16152635
asta	CONCORDANT	90%	HER2 is overexpressed in 20%-25% of breast cancer patients. HER2 over-expression is known as an aggressive tumor phenotype and is associated with worse survival Asta's retrieved literature gives an overlapping 20-25% frequency and ties HER2 overexpression to an aggressive phenotype and worse survival. PMID:33013420

The anti-HER2 monoclonal antibody trastuzumab is the backbone of HER2-targeted therapy and, beyond signaling blockade, engages Fc-mediated immune effector mechanisms including antibody-dependent cell-mediated cytotoxicity (ADCC).

UNANIMOUS INTEGRATED

treatmentpathophysiology

Provider	Stance	Score	Evidence
falcon	CONCORDANT	90%	Trastuzumab engages Fcγ receptors on NK cells and macrophages, mediating ADCC/ADCP and contributing significantly to efficacy Falcon describes trastuzumab's Fc-mediated ADCC/ADCP immune effector activity as a major contributor to efficacy. DOI:10.3390/cancers16152635
asta	CONCORDANT	85%	finding that the drug induces antibody-dependant cell-mediated cytotoxicity Asta's retrieved clinical study reports trastuzumab inducing antibody-dependent cell-mediated cytotoxicity, matching the ADCC immune-effector claim. DOI:10.37358/rc.19.8.7428

Reactivation of PI3K/AKT signaling — via PIK3CA activating mutations and PTEN loss — is a central mechanism of resistance to anti-HER2 therapies.

UNANIMOUS INTEGRATED

treatmentpathophysiology

Provider	Stance	Score	Evidence
falcon	CONCORDANT	95%	PIK3CA activating mutations and PTEN loss restore downstream signaling and drive resistance to trastuzumab, pertuzumab, TKIs, and ADCs Falcon names PIK3CA activating mutations and PTEN loss as PI3K/AKT-reactivating drivers of resistance across mAbs, TKIs, and ADCs. DOI:10.3390/ijms252413376
asta	CONCORDANT	90%	loss of PTEN leading to activation of the PI3K/Akt/mTOR pathway, PI3KCA mutation, and Akt mutation or amplification were common causes of drug resistance Asta's retrieved literature independently names PTEN loss and PIK3CA mutation activating PI3K/AKT/mTOR as common causes of anti-HER2 drug resistance. PMID:33688205

HER2-positive metastatic disease has a high propensity for brain metastases, with roughly 25-50% of patients developing CNS involvement over the disease course.

SINGLE INTEGRATED

phenotype

Provider	Stance	Score	Evidence
falcon	CONCORDANT	90%	Approximately 25–50% of patients with HER2-positive breast cancer experience brain metastases. Falcon quantifies the frequent brain-metastasis burden (25-50%) as a defining clinical feature of HER2-positive disease. DOI:10.3390/biomedicines13051153
asta	SILENT	—	Asta's retrieval-only report is focused on resistance mechanisms and biomarkers and does not address CNS tropism or brain metastasis.

Modern antibody-drug conjugates (e.g., trastuzumab deruxtecan/T-DXd) with cleavable linkers and membrane-permeable payloads produce bystander killing that enhances efficacy in antigen-heterogeneous tumors.

MAJORITY INTEGRATED

treatmentpathophysiology

Provider	Stance	Score	Evidence
falcon	CONCORDANT	90%	Modern ADCs (e.g., T-DXd) use cleavable linkers and membrane-permeable payloads to produce bystander killing, enhancing efficacy in heterogeneous tumors Falcon describes the ADC bystander-killing mechanism (cleavable linker, permeable payload) and its benefit in heterogeneous tumors. DOI:10.3390/ijms252413376
asta	PARTIAL	40%	the antibody-drug conjugate (ADC) trastuzumab-emtansine (T-DM1) and the reversible HER2 inhibitor lapatinib. New agents, such as trastuzumab-deruxtecan or tucatinib in combination with capecitabine and trastuzumab, have also shown a significant improvement in the metastatic setting. Asta's retrieved literature names the ADC class (T-DM1, trastuzumab-deruxtecan) and their clinical benefit but does not describe the bystander-killing mechanism — coverage of the agents without the mechanistic claim. PMID:35884366

A substantial fraction of HER2-positive tumors co-express the estrogen receptor (triple-positive/HR+ HER2+ disease), and ER-HER2 crosstalk provides a route of escape from anti-HER2 therapy.

MAJORITY INTEGRATED

treatmentpathophysiology

Provider	Stance	Score	Evidence
falcon	CONCORDANT	90%	Approximately half of HER2+ tumors express ER; bidirectional crosstalk allows ER-driven escape from anti-HER2 therapy Falcon quantifies ER co-expression (~half) and names bidirectional ER-HER2 crosstalk as a mechanism of escape from anti-HER2 therapy. DOI:10.3390/ijms252413376
asta	PARTIAL	50%	Other therapeutic strategies to overcome treatment resistance have been explored in HER2+ BC, mainly in HER2+ that also overexpress estrogen receptors (ER+). Asta's retrieved literature identifies ER-co-expressing HER2+ (triple-positive) disease as a resistance context needing added strategies, but does not spell out the bidirectional ER-HER2 crosstalk mechanism. PMID:35884366

Circulating serum metabolites (e.g., L-arginine and arachidonic acid) are altered in HER2-positive breast cancer and have been proposed as diagnostic and trastuzumab-response biomarkers.

SINGLE LEAD

diagnosis

Provider	Stance	Score	Evidence
asta	CONCORDANT	80%	L-arginine and arachidonic acid were elevated in trastuzumab-responsive and trastuzumab-resistant HER2-positive breast cancer patients Asta surfaces a metabolomics study identifying specific serum metabolites as diagnostic/response biomarkers — a lead not covered by Falcon. PMID:34994982
falcon	SILENT	—	Falcon's pathophysiology-focused report references signaling metabolites (PIP2/PIP3) but does not address circulating serum metabolite biomarkers for diagnosis or trastuzumab response.

Narrative

Overview

The two providers approach HER2-positive breast cancer from complementary angles. Falcon delivers a synthesized, mechanism-first pathophysiology report that walks from ERBB2 amplification through downstream signaling, resistance biology, immune/ADC pharmacology, CNS tropism, and clinical phenotype. Asta is retrieval-only: it returns a ranked list of 18 papers with extracted snippets and performs no second-stage synthesis, so its "view" of the disorder is the union of what those papers happen to emphasize — heavily weighted toward resistance mechanisms, biomarkers, and therapy prediction. Despite the format gap, both converge on the same causal spine: HER2/ERBB2 as an amplified, ligand-independent oncogenic driver signaling through PI3K/AKT/mTOR and RAS-MAPK, treated with trastuzumab-based anti-HER2 therapy.

Agreement

Convergence is strong on the core biology. Both frame ERBB2 amplification/overexpression as the oncogenic driver of proliferation, survival, and malignant transformation, and both name the PI3K/AKT/mTOR and RAS-MAPK cascades as the effector pathways. They agree on epidemiology (falcon's ~15-25% overlaps asta's 20-25%) and on the aggressive, poor-prognosis phenotype. Both position trastuzumab as the therapy backbone and independently note its Fc-mediated ADCC immune-effector activity. Most notably, they independently converge on PI3K/AKT reactivation — via PIK3CA activating mutation and PTEN loss — as a central mechanism of resistance to anti-HER2 therapy, a claim well supported on both sides.

Divergence

Divergence is by coverage, not conflict — no direct contradictions were found, and the overlapping prevalence figures are compatible rather than opposed. Falcon's unique contributions are the high brain-metastasis burden (~25-50% of metastatic patients) with its BBB/CNS-tropism rationale, and the ADC bystander-killing mechanism (cleavable linker, membrane-permeable payload); asta names the ADC agents (T-DM1, trastuzumab-deruxtecan) but not the mechanism, and is entirely silent on CNS involvement. Asta's unique contribution is a metabolomics lead — specific circulating serum metabolites (L-arginine, arachidonic acid) proposed as diagnostic and trastuzumab-response biomarkers — which falcon does not address. Falcon reads as a coherent mechanistic narrative; asta reads as a resistance/biomarker-oriented evidence pool.

Integration

The concordant core is ready to promote into the disorder YAML: the ERBB2 amplification driver, HER2/HER3 ligand-independent signaling through PI3K/AKT/mTOR and RAS-MAPK, the ~15-25% aggressive-phenotype epidemiology, the trastuzumab backbone with ADCC immune effector activity, PI3K/AKT-reactivation resistance (PIK3CA mutation, PTEN loss), the frequent brain-metastasis burden, the ADC bystander mechanism, and ER-HER2 crosstalk in triple-positive disease. These are each supported by at least one provider with concordant framing and, for most, corroborated across both. Underlying PMIDs/DOIs should be fetch-verified and re-quoted through the main curation pipeline before the literature evidence blocks and ontology terms are attached.

Not integrated (leads)

The circulating-metabolite biomarker claim (L-arginine and arachidonic acid as diagnostic/trastuzumab-response markers) is retained as a LEAD rather than promoted: it rests on a single small metabolomics study surfaced only by asta, is not corroborated by falcon, and needs independent verification before it would justify a diagnosis-section entry. It is a promising direction for future curation but not yet integration-ready.

Cross-provider synthesis comparing falcon (a synthesized, pathophysiology-focused report, 19 citations) and asta (a retrieval-only literature listing of 18 papers with extracted snippets, no second-stage synthesis). The two agree strongly on the core biology: ERBB2 amplification/overexpression as oncogenic driver, PI3K/AKT/mTOR and RAS-MAPK signaling, ~15-25% prevalence with aggressive phenotype, trastuzumab plus ADCC as therapy backbone, and PI3K/AKT reactivation (PIK3CA mutation, PTEN loss) as a central resistance mechanism. No direct contradictions were found; divergence is by coverage — falcon adds CNS/brain-metastasis burden and the ADC bystander mechanism that asta does not describe (asta names the ADC agents but not the mechanism), while asta surfaces a circulating-metabolite biomarker lead absent from falcon. best_matching_text values are verbatim excerpts from the cited report files; literature evidence snippets and ontology terms are intentionally left to the main curation pipeline on the disorder YAML.